Second Heart Assist
Second Heart Assist is dedicated to improving the quality of life for heart failure patients through innovative minimally invasive circulatory support devices. Their mission is to develop advanced, minimally invasive solutions that provide high flow rates, reduce hemolysis, and address major heart failure markets with both catheter-based and wireless powered platforms. They aim to support patients with acute and chronic heart failure, high-risk PCI, and cardiogenic shock, leveraging proprietary technology and a strong intellectual property portfolio.
Industries
Nr. of Employees
small (1-50)
Second Heart Assist
340 E 400 S. Ste 225, Salt Lake City, UT 84111
Patents
Products
Catheter-based percutaneous circulatory assist pump (temporary use)
Low-profile, collapsible stent pump delivered percutaneously to the aorta to provide temporary circulatory support during high-risk PCI, acute decompensated heart failure and cardiogenic shock.
Wirelessly powered implantable circulatory assist pump (chronic use)
Implantable circulatory assist system powered via transcutaneous wireless power transfer intended for chronic ambulatory support and extended outpatient therapy.
Catheter-based percutaneous circulatory assist pump (temporary use)
Low-profile, collapsible stent pump delivered percutaneously to the aorta to provide temporary circulatory support during high-risk PCI, acute decompensated heart failure and cardiogenic shock.
Wirelessly powered implantable circulatory assist pump (chronic use)
Implantable circulatory assist system powered via transcutaneous wireless power transfer intended for chronic ambulatory support and extended outpatient therapy.
Services
Planning and execution of investigational device studies including OUS and first-in-human cases to collect safety and efficacy data for regulatory submissions.
Bench performance evaluations, comparative hemolysis testing and large-animal studies to benchmark device performance against existing technologies.
Identification of regulatory pathways and clinical site selection in support of FDA and CE Mark trials for medical devices.
Preparation and maintenance of patent filings covering pump architectures, wireless power transmission, deployment systems and related device technologies.
Planning and execution of investigational device studies including OUS and first-in-human cases to collect safety and efficacy data for regulatory submissions.
Bench performance evaluations, comparative hemolysis testing and large-animal studies to benchmark device performance against existing technologies.
Identification of regulatory pathways and clinical site selection in support of FDA and CE Mark trials for medical devices.
Preparation and maintenance of patent filings covering pump architectures, wireless power transmission, deployment systems and related device technologies.
Expertise Areas
- Clinical trial management for investigational cardiovascular devices
- Mechanical circulatory support device design
- Percutaneous catheter delivery systems
- Transcutaneous wireless power systems for implants
Key Technologies
- Nitinol aortic radial stent
- Percutaneous catheter-based delivery
- Pulsatile pump architecture
- Open-frame impeller design
News & Updates
In a US FDA-mandated comparative study, Second Heart Assist validated its Whisper device’s ability to demonstrate significantly lower hemolysis compared to the only approved device on the market today, Johnson & Johnson.
Second Heart Assist concludes yet a third highly-successful trial in South America targeted at High Risk PCI, providing solid data on safety and efficacy, including high-volume perfusion to kidneys, hemodynamic support, and ultra-low hemolysis.
Second Heart Assist announced continued successes in additional clinical studies in South America, demonstrating high levels of safety and efficacy of the Whisper device in supporting multiple indications of heart failure.
The company completed its first Central American case to evaluate the performance of its Whisper™ percutaneous mechanical circulatory device, demonstrating promising results.
Discussion on the history and future of ventricular assist devices and mechanical circulatory support, featuring experts in the field.
In a US FDA-mandated comparative study, Second Heart Assist validated its Whisper device’s ability to demonstrate significantly lower hemolysis compared to the only approved device on the market today, Johnson & Johnson.
Second Heart Assist concludes yet a third highly-successful trial in South America targeted at High Risk PCI, providing solid data on safety and efficacy, including high-volume perfusion to kidneys, hemodynamic support, and ultra-low hemolysis.
Second Heart Assist announced continued successes in additional clinical studies in South America, demonstrating high levels of safety and efficacy of the Whisper device in supporting multiple indications of heart failure.
The company completed its first Central American case to evaluate the performance of its Whisper™ percutaneous mechanical circulatory device, demonstrating promising results.
Discussion on the history and future of ventricular assist devices and mechanical circulatory support, featuring experts in the field.